前瞻性基因组引导识别「早期/演化中」和「取样不足」的IDH野生型胶质母细胞瘤可改善临床结局
该研究对38例组织学缺乏坏死或微血管增生但基因组符合胶质母细胞瘤分子特征的IDH野生型弥漫性星形细胞瘤患者进行前瞻性基因组分析,识别出「早期/演化中」和「取样不足」两种胶质母细胞瘤临床情景。与仅基于组织形态学诊断接受标准治疗的历史对照队列相比,基因组引导识别使患者管理更积极并改善临床结局。
要点
- 组织学低级别但分子特征符合胶质母细胞瘤的IDH野生型弥漫性星形细胞瘤可分为「早期/演化中」和「取样不足」两类。
- 前瞻性基因组引导识别使患者管理更积极并改善临床结局。
- 作者支持常规使用基因组和/或表观基因组分析以准确分类胶质肿瘤。
核心结论
- 前瞻性基因组引导识别早期/演化中和取样不足的IDH野生型胶质母细胞瘤,使患者管理更积极并改善临床结局。
- 结果支持常规使用基因组和/或表观基因组分析来准确分类胶质肿瘤,因为这些检测不仅改善诊断分类,还关键性地促成更合适的患者管理从而改善临床结局。
研究设计与样本
- 对38例连续成人IDH野生型弥漫性星形细胞瘤患者进行前瞻性临床基因组分析,这些患者组织学检查无坏死或微血管增生。
- 基因组分析揭示符合cIMPACT-NOW标准的「弥漫性星形细胞瘤,IDH野生型,伴胶质母细胞瘤分子特征,WHO IV级」整合诊断标准。
- 分析这些患者的临床管理和结局,并与接受基于组织形态学诊断的标准治疗、生物学匹配的历史对照患者队列进行比较。
主要发现
- 该诊断基于影像学、组织学和基因组学特征的整合,包含「早期/演化中」和「取样不足」两种不同的临床情景。
- 与生物学匹配的历史对照队列相比,前瞻性基因组引导识别早期/演化中和取样不足的IDH野生型胶质母细胞瘤导致更积极的患者管理并改善临床结局。
临床怎么用
- 作者支持常规使用基因组和/或表观基因组分析来准确分类胶质肿瘤,因为这些检测不仅改善诊断分类,还关键性地促成更合适的患者管理从而改善临床结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic profiling studies of diffuse gliomas have led to new improved classification schemes that better predict patient outcomes compared to conventional histomorphology alone. One example is the recognition that patients with IDH-wildtype diffuse astrocytic gliomas demonstrating lower-grade histologic features but genomic and/or epigenomic profile characteristic of glioblastoma typically have poor outcomes similar to patients with histologically diagnosed glioblastoma. Here we sought to determine the clinical impact of prospective genomic profiling for these IDH-wildtype diffuse astrocytic gliomas lacking high-grade histologic features but with molecular profile of glioblastoma. METHODS: Clinical management and outcomes were analyzed for 38 consecutive adult patients with IDH-wildtype diffuse astrocytic gliomas lacking necrosis or microvascular proliferation on histologic examination that were genomically profiled on a prospective clinical basis revealing criteria for an integrated diagnosis of "diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV" per cIMPACT-NOW criteria. RESULTS: We identified that this diagnosis consists of two divergent clinical scenarios based on integration of radiologic, histologic, and genomic features that we term "early/evolving" and "undersampled" glioblastoma, IDH-wildtype. We found that prospective genomically guided identification of early/evolving and undersampled IDH-wildtype glioblastoma resulted in more aggressive patient management and improved clinical outcomes compared to a biologically matched historical control patient cohort receiving standard-of-care therapy based on histomorphologic diagnosis alone. CONCLUSIONS: These results support routine use of genomic and/or epigenomic profiling to accurately classify glial neoplasms, as these assays not only improve diagnostic classification but critically lead to more appropriate patient management that can improve clinical outcomes.
引用
- Zhang Y, Lucas CG, Young JS, et al. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022. PMID: 35395677. doi:10.1093/neuonc/noac089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。